WINZOR PHARMACEUTICALS UK LIMITED

Company Registration Number:
07533771 (England and Wales)

Unaudited statutory accounts for the year ended 28 February 2025

Period of accounts

Start date: 1 March 2024

End date: 28 February 2025

WINZOR PHARMACEUTICALS UK LIMITED

Contents of the Financial Statements

for the Period Ended 28 February 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes

WINZOR PHARMACEUTICALS UK LIMITED

Directors' report period ended 28 February 2025

The directors present their report with the financial statements of the company for the period ended 28 February 2025

Principal activities of the company

Pharmaceuticals export



Directors

The directors shown below have held office during the whole of the period from
1 March 2024 to 28 February 2025

Mr Taghlub Al-KASS
DanA AL-KASS
Tara AL-KASS


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
26 June 2025

And signed on behalf of the board by:
Name: Mr Taghlub Al-KASS
Status: Director

WINZOR PHARMACEUTICALS UK LIMITED

Profit And Loss Account

for the Period Ended 28 February 2025

2025 2024


£

£
Turnover: 1,878,884 1,578,227
Cost of sales: ( 1,056,523 ) ( 765,812 )
Gross profit(or loss): 822,361 812,415
Administrative expenses: ( 795,977 ) ( 800,167 )
Operating profit(or loss): 26,384 12,248
Profit(or loss) before tax: 26,384 12,248
Tax: ( 1,514 ) ( 2,327 )
Profit(or loss) for the financial year: 24,870 9,921

WINZOR PHARMACEUTICALS UK LIMITED

Balance sheet

As at 28 February 2025

Notes 2025 2024


£

£
Fixed assets
Tangible assets: 3 804,961 804,961
Total fixed assets: 804,961 804,961
Current assets
Stocks: 4 338,324 488,324
Debtors: 5 424,673 254,991
Cash at bank and in hand: 174,714 185,758
Total current assets: 937,711 929,073
Creditors: amounts falling due within one year: 6 ( 60,931 ) ( 77,163 )
Net current assets (liabilities): 876,780 851,910
Total assets less current liabilities: 1,681,741 1,656,871
Creditors: amounts falling due after more than one year: 7 ( 486,258 ) ( 486,258 )
Total net assets (liabilities): 1,195,483 1,170,613
Capital and reserves
Called up share capital: 99 99
Profit and loss account: 1,195,384 1,170,514
Total Shareholders' funds: 1,195,483 1,170,613

The notes form part of these financial statements

WINZOR PHARMACEUTICALS UK LIMITED

Balance sheet statements

For the year ending 28 February 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 26 June 2025
and signed on behalf of the board by:

Name: Mr Taghlub Al-KASS
Status: Director

The notes form part of these financial statements

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 25 35

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 March 2024 804,961 804,961
Additions
Disposals
Revaluations
Transfers
At 28 February 2025 804,961 804,961
Depreciation
At 1 March 2024
Charge for year
On disposals
Other adjustments
At 28 February 2025
Net book value
At 28 February 2025 804,961 804,961
At 29 February 2024 804,961 804,961

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

4. Stocks

2025 2024
£ £
Stocks 338,324 488,324
Total 338,324 488,324

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

5. Debtors

2025 2024
£ £
Trade debtors 190,673 254,991
Other debtors 234,000
Total 424,673 254,991

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

6. Creditors: amounts falling due within one year note

2025 2024
£ £
Trade creditors 59,417 74,836
Taxation and social security 1,514 2,327
Total 60,931 77,163

WINZOR PHARMACEUTICALS UK LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2025

7. Creditors: amounts falling due after more than one year note

2025 2024
£ £
Other creditors 486,258 486,258
Total 486,258 486,258